Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q4 2021 Earnings Presentation
19 slides from Arcticzymes Technologies Asa's earnings presentation, 2022
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights - Q4 and 2021 2 Business Update 3 Financials 4 Outlook 2022 and Beyond
Slide 3: Highlights
Highlights
Slide 4: Highlights Q4 2021
Highlights Q4 2021 Achieved status as a profitable and high-growth standalone enzyme company Positive cash contribution Expansion Highest quarterly continues. Cash completed sales ever balance New 500m2 40.5 MNOK 200 MNOK production facility Innovations Exceeded annual delivered sale target achievin
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Commercial Segment Sales
Business Updates Commercial Segment Sales Biomanufacturing Molecular Tools (Research & Diagnostics) ✓ 29% quarterly growth versus Q4 2020 ✓ 123% quarterly growth versus Q4 2020 ✓ 13% annual growth versus 2020 ✓ 54% annual growth versus 2020 ✓ Main growth driver is non-coronavirus related sales ✓ Res
Slide 7: Business Updates: Coronavirus-related sales
Business Updates Coronavirus-related sales 23% contribution of total Q4 sales 26% contribution of 2021 annual sales Increase in Q4 sales correlates with the demand for testing following the Omicron outbreak. Visibility and impact of Coronavirus become more difficult to quantity Suspect some of the r
Slide 8: Business Update: Innovations
Business Update Innovations Three new products launched ArcticZymes R2DTM Ligase - Patent pending and novel ligase IsoPol® BST+ High concentration Glycerol FREE - DNA polymerase M SAN HQ ELISA kit - support product for M-SAN enzyme M SAN HQ manufacturing successful upscaled Commercial availability t
Slide 9: Business Update: Operations
Business Update Operations New 500 m2 production facility at the SIVA innovations Centre opened and operational State-of-the-art facility for the scalable enzyme manufacturing to support organic growth over the next 4-5 years New “common" fermentation room Conforms to the strict requirements demande
Slide 10: Business Updates: Strategic Growth Initiatives
Business Updates Strategic Growth Initiatives AZT remains committed to execute on its strategic growth initiatives Organic growth Establishment of laboratory in Oslo focusing on applications development is progressing according to plan Expect to be operational within Q2 2022 Inorganic growth Continu
Slide 11: Financials
Financials
Slide 12: ArcticZymes Sales Q4 2021
ArcticZymes Sales Q4 2021 Growth in biomanufacturing and Molecular Tools Sales per segment 50 000 Biomanufacturing Sales increase of 84% compared to same 45 000 Amounts in NOK 1.000' Research and Diagnostics quarter last year 40 000 Achieved 40.5 MNOK (22.1 MNOK) 35 000 Currency continues to have ne
Slide 13: ArcticZymes Sales Q4 2021: Coronavirus-related sales
ArcticZymes Sales Q4 2021 Coronavirus is considered part of the underlaying business Estimated Coronavirus related sales Amounts in NOK 1.000' 18 000 16 000 14 000 12 000 Sales in TNOK 10 000 8 000 6 000 4 000 2 000 - Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 13
Slide 14: 12 Month rolling average quarterly sales
12 Month rolling average quarterly sales Growth trend continues Amounts in NOK 1.000' 35 000 30 000 Sales development 25 000 Sales development ex Covid-19 20 000 15 000 10 000 5 000 - Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 14
Slide 15: Profitability and expenses
Profitability and expenses Investments in organic growth influences our figures Amounts in NOK 1.000' 45 000 Sales 40 000 Quarterly Sales (MNOK 40.5 vs. 22.1) EBITDA 35 000 30 000 EBITDA increased by 14.0 MNOK (MNOK 20.8 vs 6.8) 25 000 20 000 Expenses increased by 1.8 MNOK 15 000 Increase in personn
Slide 16: Cash Flow
Cash Flow 14 MNOK in positive cash flow Amounts in NOK 1.000' 250 000 90 000 80 000 Net Cash 200 000 Changes in Cash 70 000 60 000 Changes in cash 150 000 50 000 Net Cash 40 000 100 000 30 000 20 000 50 000 10 000 0 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 16 All figures are a
Slide 17: Outlook
Outlook
Slide 18: Outlook 2022 and Beyond
Outlook 2022 and Beyond Updated financial guidance The Company outlook for 2022 Annual sales target of NOK 155 million Quarterly fluctuations will continue Lower contribution from coronavirus-related sales Expanded innovation activities into the Oslo region Further new product launches and upscaling
Slide 19: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com
ArcticZymes Technologies — Q4 2021 Earnings Presentation on 6ix